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Sialic Acid Storage Disease and Related Disorders
E.M. STREHLE
ABSTRACT
This paper gives an overview of the two sialic acid storage disorders, Salla disease and infantile sialic acid
storage disease, and the related disorders cystinosis, sialuria, sialidosis, and galactosialidosis. Sialic acid stor-
age disease and cystinosis are models for a deficient lysosomal transport of monosaccharides and amino acids,
respectively. Several gene mutations leading to the production of the faulty membrane proteins sialin and
cystinosin have been identified in recent years. Knowledge of the underlying pathophysiology is a prerequi-
site for future research projects, which will focus on the expression of the disease genes in living systems and
the physical characterization of these proteins by X-ray crystallography and nuclear magnetic resonance spec-
troscopy.
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INTRODUCTION
SIALIC ACID STORAGE DISORDERS (SASD) belong to the cate-gory of rare lysosomal storage diseases and can be divided
into the adult-type Salla disease (SD) (OMIM 604369) and the
more severe infantile sialic acid storage disease (ISSD; OMIM
269920). So far less than 150 cases, predominantly from Fin-
land, have been reported. As in many other inborn errors of me-
tabolism, the mode of inheritance is autosomal recessive. Pa-
tients with these progressive disorders show varying degrees of
neurodevelopmental delay and learning difficulties. The stor-
age of free sialic acid in the body and its excretion in the urine
is increased up to 100 times. SASD are caused by a defective
molecular transport mechanism, that leads to an accumulation
of unbound sialic acid within the lysosomes (Gahl et al., 1985).
Recently the gene responsible for the defect has been located
on the long arm of chromosome 6. This gene encodes a trans-
membrane protein, sialin (OMIM 604322), which is a member
of the major facilitatorsuperfamily (MFS). The MFS comprises
a large number of proteins involved in intra- and intercellular
transfer of metabolites (Verheijen et al., 1999). Sialidosis and
galactosialidosisare characterized by intralysosomal storage of
sialyl-oligosaccharides, which is caused by a deficiency of the
enzyme sialidase. In contrast, sialuria is the result of an in-
creased synthesis of sialic acids in the cytoplasm secondary
to a lack of feedback inhibition of the rate-limiting enzyme
(Fig. 1).
SIALIC ACID STORAGE DISORDERS
Salla disease
In 1978, Aula and colleagues described three adult brothers
and their female cousin from an institution for disabled people
in Finland whose clinical picture was suggestive of a new lyso-
somal storage disease (Aula et al., 1978). Their signs and symp-
toms were coarse facial features, dysarthria, clumsiness, ataxia,
and severe learning difficulties.The skull bones were thickened
on radiographyand the electroencephalogram was diffusely ab-
normal. The blood film revealed between 4% and 15% vacuo-
lated lymphocytes,but the activitiesof eight lysosomal enzymes
were normal. The concentration of total sialic acid in the urine
was three to four times higher than in controls. On electron mi-
croscopy, large lysosomal storage vacuoles were detected in
several types of skin cells, including Schwann cells, eccrine
gland cells, and cultured fibroblasts (Aula et al., 1979). All pa-
tients had an uneventful neonatal period. The first signs of de-
lay were present at 1 year of age, and a significant deteriora-
tion was observed during the second decade. In view of the
unknown etiology, the condition was named Salla disease (SD)
after the region in northeasternFinland where the patients lived.
Using various chromatographictechniques,Renlund and co-
workers examined urine specimens from 13 patients, who met
the criteria for SD, and 24 healthy individuals. Gel chro-
matography revealed a characteristic sialic acid pattern in SD
Northern Health Centre, London WC1E 7HX, England, UK.
patients.One main peak (V) was analyzed further by combined
gas-liquid chromatography/mass spectrometryand identified as
N-acetylneuraminicacid (NANA or NeuAc). Urinary excretion
of free (unbound) sialic acid ranged from 50.3 to 140.0 mg/mg
creatinine in patients and 2.3–8.8 mg/mg in controls. The pro-
portion of free to total sialic acid was increased about five-fold
(Renlund et al., 1979). The same authors collected data on 34
Finnish patients, who belonged to 23 partly interrelated fami-
lies from the Salla district. They were between 2 years 9 months
and 63 years old; 20 of them were male, and most had a nor-
mal birth history. Their intelligence quotient (IQ) did not ex-
ceed 40, and short stature was present in 18 affected adults
(Renlund et al., 1983a).
Radioactive labeling studies were performed on skin fibro-
blasts from normal individuals and from patients with SD. The
results led to the conclusion that NANA is released from the
lysosomes in mutant cells at a slower rate than from control
cells (Renlund et al., 1986a). Although SD occurs predomi-
nantly in Finland, sporadiccases from other countrieshave been
reported. Wolburg-Buchholz et al. (1985) described 3 German
siblings with a severe neurodegenerative disease leading to
death in 2 of the patients. Morphological and biochemical find-
ings were consistent with SD (Wolburg-Buchholzet al., 1985).
A 5-year old French boy was investigated for learning diffi-
culties, speech delay, hyperactivity,and ataxia. Conjunctivalbi-
opsy showed vacuolated fibroblasts and thin-layer chromatog-
raphy revealed high concentrations of free sialic acid in the
urine (Echenne et al., 1986).
It has been suggested that SD is underdiagnosed,because it
lacks the typical features of other lysosomal storage disorders
and usually becomes manifest in the second decade of life
(Robinson et al., 1997). Renlund and Aula monitored through
amniocentesis 4 pregnant mothers from families at risk of SD.
N-Acetylneuraminicacid in cultured amniocytes from one preg-
nancy was significantly raised compared to controls (2.6
nmol/mg protein vs. 0.5 nmol/mg protein). The infant devel-
oped hypotonia and nystagmus, and the diagnosis of SD was
confirmed by skin biopsy (Renlund and Aula, 1987).
The involvement of the central nervous system in SD has
been documented in several studies. Autopsy of 2 deceased pa-
tients revealed marked cerebral atrophy with loss of axons and
myelin. The number of neurons in the cortex and the basal gan-
glia was reduced, and the remaining cells showed signs of de-
generation (Autio-Harmainen et al., 1988). Haataja and co-
workers (1994a) performed magnetic resonance imaging (MRI)
on 7 SD patients, who were between 11 months and 39 years
old, and suffered from frequent seizures. They demonstrated
defective white matter myelination, hypoplastic corpus callo-
sum, and cortical and cerebellar atrophy. The MRI abnormali-
ties correlated with the clinical severity (Haataja et al., 1994a).
A Finnish research group studied the brain metabolism of
nine subjects with SD using positron emission tomography
(PET). The local cerebral metabolic rates for glucose were in-
creased in the frontal and sensorimotor cortex, and the basal
ganglia (Suhonen-Polvi et al., 1999). In about 50% of SD pa-
tients, the peripheral nervous system is also affected. Varho and
colleagues (2000) measured a decrease in motor nerve con-
duction velocities suggestive of a peripheral polyneuropathy.
So far no specific treatment for patients with SD is available.
Infantile sialic acid storage disease
In 1982 Hancock et al. reported a male infant of German-
Swedish origin, who presented at birth with severe ascites and
hepatomegaly, and died at the age of 5 months. They found
large amounts of NANA in brain, liver, and kidney tissues and
linked this condition to SD. Studies on radioactively labeled
cultured fibroblasts indicated the accumulation of free sialic
acid in the lysosomes, but normal activities of the lysosomal
enzymes. The concentration of free NeuAc in pathologic fi-
broblasts was 3.5 6 0.7 mmol/gram fresh weight compared to
0.2 6 0.04 mmol/gram in control fibroblasts (Hancock et al.,
1982, 1983). Tondeur and Stevenson and their colleagues de-
lineated the infantile form of sialic acid storage disease further
on the basis of 4 non-Finnish patients (Tondeur et al., 1982;
Stevenson et al., 1983). The clinical features in these cases were
sparse hair, coarse facies, hypopigmentation, hepatospleno-
megaly, developmental delay, failure to thrive, and death in in-
fancy. Vacuolated lymphocytes were present in blood and bone
marrow smears, and the urinary excretionof unboundsialic acid
was increased 20- to 60-fold.
Infantile sialic acid storage disease differs from SD inso-
far as its onset is earlier, the physical signs are more pro-
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FIG. 1. Schematic representation of the metabolic pathways
in: A, sialic acid storage disease; B, cystinosis; C, sialuria; D,
sialidosis;and E, galactosialidosis(NANA, N-acetylneuraminic
acid; 2-epimerase, uridine diphosphate N-acetylglucosamine2-
epimerase).
nounced,and it progresses much more rapidly. Unlike SD,
ISSD is not limited to Finland, but has been observed in sev-
eral patients from Europe, Northern America, and Australia
(Cooper et al., 1988; Clements et al., 1988; Pueschel et al.,
1988; Levebre et al., 1999; Sperl et al., 1990). Lemyre et al.
reviewed 27 cases of ISSD and listed as additional findings
hydrops fetalis, cardiomegaly, nephrotic syndrome, and death
at a mean age of 13.1 months (Lemyre et al., 1999). Berra
and colleagues performed extensive electron microscopical
and biochemical studies on a female infant with ISSD, who
died at the age of 3 months. Storage of free sialic acid was
seen in brain, liver, spleen, kidneys, and cultured skin fibro-
blasts. While the tissue content of total cholesterol, phospho-
lipids, and glycolipids was within normal limits, significant
changes were noted in the distribution of complex membrane
lipids (Berra et al., 1995).
The underlying pathomechanism of ISSD is an impaired
transport of free sialic acid and glucuronic acid (GlcUA) across
the lysosomalmembrane (Tietze et al., 1989;Blom et al., 1990).
Vamos and co-authors (1986) diagnosed ISSD in a 17-week-
old fetus using amniocentesis. The fetus was subsequently
aborted, and ultrastructural examination revealed fibrillo-gran-
ular storage material in all cell types (Vamos et al., 1986). It is
also possible to diagnose ISSD morphologically and biochem-
ically on chorion villus samples at 10 weeks gestation (Lake et
al., 1989). Only supportive treatment can be offered to children
with ISSD.
Intermediate types
Some of the Finnish patients with SD and single cases from
other parts of Europe presented in an atypical way that was
more severe and included clinical findings usually only seen in
ISSD. A 4-year-old boy of consanguinous Italian parents had
mild dysmorphic features and hepatosplenomegaly at birth.
During the first year of life, he required several admissions to
hospital because of respiratory tract infections. His develop-
mental milestones were delayed, his gait was broad based, and
he was hypertonic. Numerous vacuolated cells were observed
in blood, skin, and liver cells, and urinary free sialic acid was
increased. The authors concluded that this case showed char-
acteristics of both ISSD and SD, possibly due to allelic muta-
tions (Baumkoetter et al., 1985). Ylitalo and co-workers de-
scribed 2 unrelated Swedish girls, who were initially thought
to have ataxic and dyskinetic cerebral palsy, respectively.Their
severe motor disability was associated with a normal early in-
tellectual development. The concentration of free sialic acid in
the urine was moderately high and storage lysosomeswere pres-
ent in Schwann cells and fibrocytes. They suggested, that these
children had variants of SD (Ylitalo et al., 1986).
Schleutker et al. (1995b) compared the different phenotypes
of SASD and delineated an intermediate type in four non-
Finnish children with severe psychomotordelay during the first
decade.One of them also developedcorneal opacities and ovoid
deformation of the lumbar vertebral bodies (Fois et al., 1987;
Mancini et al., 1992b; Schleutker et al., 1995b). The number
of reported patients with SASD worldwide is about 150.
Therefore, it is likely that with increasing case reports the spec-
trum of these heterogeneousdisorders will become more trans-
parent.
RELATED DISORDERS
Cystinosis
Like SD and ISSD, cystinosis (OMIM 219800) is an auto-
somal recessive lysosomal storage disorder, which was first de-
scribed by Abderhalden (1903). There are two main variants of
cystinosis: the nephropathic type, which can be further subdi-
vided depending on the age of onset; and the nonnephropathic,
benign type. According to a French study, its overall incidence
lies between 1 in 26,000 and 1 in 326,000 (Bois et al., 1976).
Cystinosis is caused by a deficient lysosomal carrier system,
that normally enables the amino acid cystine to leave the lyso-
some for further degradation. This results in deposition of cys-
tine in various body tissues, particularly in kidneys, eyes, thy-
roid, pancreas, and gonads. Musculature and the nervous and
gastrointestinalsystems are, to a lesser extent, affected, as well.
Infants with cystinosis are well at birth, but show symptoms of
renal tubular acidosis (Fanconi syndrome) after 6 months. They
have a reduced appetite and poor weight gain. Polyuria and
polydipsia lead to recurrent dehydration and acidosis secondary
to loss of water, electrolytes, and other small molecules. Later,
the children develop photophobia and most of them require re-
nal dialysis or a kidney transplant by the age of 10 years. The
diagnosis is made by measuring the concentration of cystine in
blood leukocytes or skin fibroblasts. Prenatal diagnosis using
amniocytes and chorion villus specimens is also available.
The prognosis of cystinosis patients has greatly improved
since the introductionof oral cysteamine treatment. Cysteamine
lowers the cystine content of affected cells rapidly and delays
the disease process significantly. After entering the lysosome,
cysteamine forms a complex with one cysteine residue of the
cystine molecule, and then exits the lysosome via an alterna-
tive pathway (Gahl et al., 1995).
In 1995 the Cystinosis Collaborative Research Group inves-
tigated 43 cystinosis patients with 23 families to establish link-
age between the gene for cystinosis and 328 microsatellite
markers. They were able to assign the gene locus to a short seg-
ment on chromosome 17p, between the markers D17S1583 and
D17S796 (McDowell et al., 1995). Town and co-authors re-
fined the critical region further and identified a new gene on
chromosome17p13 that is deleted in 33% of homozygouscysti-
nosis patients. The latter CTNS gene encodes the lysosomal
membrane protein “cystinosin,” which consists of 367 amino
acids and has six or seven predicted transmembrane domains
(Town et al., 1998).
Mutation screening and haplotype analysis of 34 cystinosis
patients revealed 24 different mutations, the commonest being a
57-kb deletion. These mutations impair the function of the trans-
port protein “cystinosin” to varying degrees and are responsible
for the different phenotypic presentations (Attard et al., 1999).
Touchman et al. (2000) constructed a high-resolution physical
map of the region containing the CTNS gene and detected a sec-
ond gene, CARKL, in this region that encodes a carbohydrateki-
nase. Both genes are deleted in approximately half of the ho-
mozygous cystinosis patients (Touchman et al., 2000).
Sialuria
Sialuria (OMIM 269921) was first reported in a 2.5-year-old
French boy in 1968 (Fontaine et al., 1968; Montreuil et al.,
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1968).He presented with facial dysmorphism, skeletal abnor-
malities, failure to thrive, developmental delay, epilepsy, he-
patomegaly, and metabolic acidosis. Thin-layer chromatogra-
phy of his urine revealed an elevated daily excretion of 5.8
grams to 7.2 grams of NeuAc. Since then, only 3 further cases
from Australia and America have been published (Wilcken et
al., 1987; Seppala et al., 1991; Krasnewich et al., 1993).
Thomas and co-workers (1985) detected more than 40 times
higher concentrations of free sialic acid in cultured skin fibro-
blasts from the original patient compared to control cells. Fur-
ther biochemical studies by the same group provided evidence
that the storage of NeuAc occurs in the cytoplasm rather than
in the lysosomes (Thomas et al., 1989).
The underlyingmetabolic defect in sialuria is the loss of feed-
back inhibitionof the rate-limitingenzyme of sialic acid biosyn-
thesis, uridine diphosphate N-acetylglucosamine 2-epimerase
(UDP-GlcNAc 2-epimerase).The chemical reaction is normally
controlledby cytidine monophosphate-N-acetylneuraminicacid
(CMP-NeuAc). This leads to enhanced enzymatic activity and
accumulation of NeuAc in the cytoplasm (Weiss et al., 1989).
Recently the gene for UDP-GlcNAc 2-epimerase on chromo-
some 9p12 was successfully cloned, and 3 heterozygous muta-
tions were identified suggesting a dominant mode of inheritance
(Seppala et al., 1999). One case of sialuria has yet to be classi-
fied. Palo and colleagues (1985) described an adult female of
Finnish origin, who had mild learning difficulties, epilepsy, and
sialuria, but no storage vacuoles on blood and biopsy samples.
The daily amount of NeuAc in the urine was 0.5 gram, which is
less than in the other sialuria patients, but similar to patients with
sialic acid storage disorders (Palo et al., 1985).
Sialidosis
Sialidosis (neuraminidase deficiency, OMIM 256550) is an
autosomal recessive lysosomal storage disease affecting the
degradation of glycoproteins. Two types of sialidosis are rec-
ognized. The milder form (type I) usually presents in the sec-
ond decade with progressive visual impairment, generalized
myoclonus, ataxia, and epilepsy. A characteristic finding is an
ocular cherry-red spot. Sialidosis type II can be divided into 3
subgroups with descending severity (congenital, infantile, and
juvenile). Physical signs include hydrops fetalis, coarse facies,
hepatosplenomegaly, skeletal abnormalities, and delayed neu-
rodevelopment (Thomas and Beaudet, 1995).
Both types are caused by a deficiency of the enzyme siali-
dase (a-neuraminidase), which removes terminal sialic acid
molecules from oligosaccharidesand glycoproteins.As a result,
these compounds accumulate in various body tissues and are
excreted in large amounts in the urine, where they can be iden-
tified by thin-layer chromatography(Strecker et al., 1977). Sial-
idase activity can be also directly measured in amniotic fluid
cells, skin fibroblasts, and leukocytes. Preliminary studies by
Mueller and co-authors (1986) suggested that the gene encod-
ing sialidase was located on the short arm of chromosome 10.
In 1996, however, Bonten and colleagues (1996) isolated the
cDNA for human a-neuraminidaseand assigned the gene to the
chromosome segment 6p21. Sialidase has a predicted molecu-
lar weight of 45 kD and consists of 415 amino acids (Bonten
et al., 1996). No curative treatment for patients with sialidosis
is currently available.
Galactosialidosis
Galactosialidosis (neuraminidase deficiency with b-galac-
tosidase deficiency, OMIM 256540) is a lysosomal storage dis-
ease closely related to sialidosis. One of the first patients with
confirmed galactosialidosis was a 12-year-old Mexican boy,
who displayed characteristics of the mucopolysaccharidoses,
sphingolipidoses, and mucolipidoses, but could not be classi-
fied clearly. He had coarse facial features, delayed neurode-
velopment, epilepsy, and cherry-red ocular spots. On electron
microscopy, cytoplasmic vacuoles were seen in hepatic Kupf-
fer cells and the activity of b-galactosidase was significantly
decreased in skin biopsy specimens. Subsequently he was also
found to be deficient for sialidase (Goldberg et al., 1971).
Currently, three categories of galactosialidosis are recog-
nized. Children with the early infantile form show hydrops fe-
talis, telangiectasias,organomegaly, skeletal abnormalities, and
a shortened life span. The late infantile type has a milder pre-
sentation,with coarse facies, cherry-red foveae, dysostosismul-
tiplex, valvularheart disease, and developmentaldelay.The ma-
jority of patientsbelong to the juvenile/adult type,which usually
manifests in the second decade and predominantly occurs in
consanguineous Japanese families. Typical findings are coarse
facies, visual impairment, spinal abnormalities, and skin le-
sions. Neurological signs include myoclonus, seizures, ataxia,
and learning difficulties.
The underlying pathomechanismof galactosialidosisis a de-
fect in the lysosomal “protective protein”/cathepsin A (PPCA),
which is related to the serine carboxypeptidases. PPCA is es-
sential for the normal activity of a-neuraminidase and delays
proteolysis of b-galactosidase.All three molecules form an en-
zyme complex. Mueller and co-authors (1986) concluded from
their genetic complementation analysis that a gene on chromo-
some 20, which is necessary for the expression of sialidase, is
nonfunctionalin galactosialidosisfibroblasts.Further in situ hy-
bridization studies assigned the gene locus for PPCA to chro-
mosome 20q13.1.Zhou et al. (1996) investigatedPPCA mRNA
in 8 patients, aged 2.5 months to 48 years, and identified sev-
eral different mutations that result in a decreased activity of
PPCA in the lysosome. They observed a correlation between
the level of PPCA and the severity of galactosialidosis (Zhou
et al., 1996).
The clinical signs of the disease are secondary to lysosomal
storage of sialyloligosaccharides in multiple organs. The diag-
nosis is confirmed by a combined assay of the deficient en-
zymes on white blood cells or cultured skin fibroblasts, and
demonstration of increased sialyloligosaccharides in the urine
by thin-layer chromatography. The treatment for patients with
galactosialidosis is symptomatic (D’Azzo et al., 1995).
SIALIC ACID METABOLISM
N-acetylneuraminic acid
Sialic acids, also called nonulosaminic acids, comprise a
group of 23 naturally occurring amino sugars with nine or more
carbon atoms. The term “sialic acids” was first proposed by
Blix et al. for all acylated neuraminic acids (Blix et al., 1957).
Due to their ability to form chemical bonds with peptides and
carbohydrates, they are found as components of oligosaccha-
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rides, polysaccharides, glycoproteins, and gangliosides (Zil-
liken et al., 1958). Sialic acids have been purified and crystal-
lized in substantial amounts from bovine and equine submax-
illary glands. They can be determined qualitativelyby the direct
Ehrlich reaction and Bial’s orcinol reaction (Blix and Lindberg,
1960). NeuAc, an amino monosaccharidein pyranose form with
a molecular weight of 309, is the basic molecule from which
other sialic acids are derived by substitution of the amino and
hydroxyl groups. NeuAc was first isolated by Gottschalk fol-
lowing interaction of the influenza B virus enzyme with uri-
nary mucoproteins (Gottschalk, 1951).
Sialic acids occur in low concentrations in many living or-
ganisms, for instance viruses, bacteria, protozoa, and vertebrates.
The plasma level of free sialic acid in healthy adults ranges from
0.5 to 1.2 nmol/ml (Seppala et al., 1990). They are commonly
located at the outer cell membrane, where they are linked a-gly-
cosidicallyin terminalpositionto galactose,N-acetylglucosamine
(GlcNAc), N-acetylgalactosamine (GalNAc), or other sialic
acids. A variety of biological functions has been attributed to
the sialic acids (Schauer, 1982). Their strong electronegative
charge provides erythrocytes and thrombocytes with a protec-
tive layer that prevents aggregation.They facilitate the binding
of positively charged molecules and increase the viscosity of
glycoproteins in mucous secretions.
Sialic acids act as components of toxin and hormone recep-
tors, including diphtheria, tetanus, cholera, insulin, and thyroid-
stimulating hormone (TSH). Ashwell and Morell (1974) first
recognized their role as biological masks. Using sialidase they
removed the sialic acid residues from radioactively labeled
ceruloplasmin exposing the terminal galactose molecules. The
resulting asialoceruloplasmindisappeared within minutes from
the serum, and increased radioactivity in the liver indicated its
degradation (Ashwell and Morell, 1974). Further examples are
the rapid elimination of desialylated erythrocytes from the
bloodstream and the regression of malignant tumor cells fol-
lowing treatment with sialidiase.
Anabolism of sialic acids
Sialic acids are synthesizedfrom hexose and hexosamine mol-
ecules, which are transformed to uridine diphosphate UDP-Glc-
NAc in the cytoplasm. UDP-GlcNAc is epimerized to N-acetyl-
mannosamine (ManNAc) and uridine diphosphate (UDP) by the
enzyme UDP-GlcNAc 2-epimerase (Sommar et al., 1972). This
is a central step of NANA biosynthesis, which is regulated via
feedback inhibition by the end product, cytidine monophosphate
N-acetylneuraminicacid (CMP-NeuAc). A defect in the feedback
mechanism leads to overproduction and lysosomal storage of
sialic acids, as seen in sialuria. Similarly, UDP-GlcNAc controls
the first enzyme in the pathway leading to its formation, gluta-
mine-fructose-6-phosphatetransaminase (Kornfeld et al., 1964).
ManNAc is converted to N-acetylmannosamine-6-phosphate,N-
acetylneuraminic acid-9-phosphate, and, finally, NeuAc. In the
cell nucleus,N-acetylneuraminicacid is activated to CMP-NeuAc
with CMP-acylneuraminate synthase and carried to the Golgi ap-
paratus by sialyltransferase (Kolisis and Hervagault, 1986).
Modification of NeuAc
The pathways leading from NeuAc to the other sialic acid
derivatives are not fully understood. One of the enzymes in-
volved is N-acetylneuraminate mono-oxygenase. This enzyme
catalyzes the hydroxylation of NeuAc in the presence of oxy-
gen, iron, ascorbic acid, and NADPH. The product of this re-
action is N-acetylglucosamine. NeuAc and GlcNAc are acety-
lated in the positions O-4, O-7, and O-9 by different
acetyltransferases(Schauer, 1982). In the Golgi apparatus, sev-
eral sialyltransferases link sialic acid residues to oligosaccha-
rides, glycoproteins, and glycolipids. The 3 main enzymes
found in the smooth endoplasmic reticulum are b-D-galacto-
side-a-(2®6)-sialyltransferase, b-D-galactoside-a-(2®3)-sia-
lyltransferase, and 2-acetamido-2-deoxy-a-D-galactoside-a-
(2®6)-sialyltransferase. The activity of the sialyltransferasesis
increased by insulin, human chorionic gonadotropin, and
platelet-aggregating compounds. Cytidine monophosphate and
its derivatives, and infection with Epstein-Barr virus have an
inhibiting effect (Schauer, 1985).
Catabolism of sialic acids
The degradation of sialylglycoconjugates takes place in the
lysosome. Specific sialidases, also called neuraminidases, re-
lease sialic acids from their glycosylic bonds by hydrolysis.
Sialidases have been found in many microorganisms and mam-
mals, where they play an important role in the modification of
immunological properties of cells. Neuraminidases are also in-
volved in the spreading of viral and bacterial infections
(Schauer, 1982). Studies on their substrate specificity revealed
that (2®3) glycosidic linkages are split at a higher rate than
(2®6) and (2®8) glycosidic bonds. An interesting phenome-
non is the relative resistance of 4-O-acetylated sialic acids to-
ward sialidases. Recently, an alternative metabolic route has
been detected in horse liver, where the 4-O-acetyl group is re-
moved by an esterase (Schauer, 1985). Unbound sialic acid is
released from the lysosome via a proton-driven carrier specific
for monosaccharides, which is situated in the lysosomal mem-
brane (Mancini et al., 1989). In the cytoplasm, NANA is sep-
arated into 2-acylamido-2-deoxy-D-mannose and pyruvate in a
reversible reaction by the enzyme acylneuraminate pyruvate-
lyase (NANA-aldolase).The resultingpyruvate supplies the cell
with energy and the 2-acylamido-2-deoxy-D-mannose is recy-
cled for the synthesis of sialic acid. Acylneuraminate pyruvate-
lyase, therefore, controls the amount of NeuAc available in
body tissues (Brunetti et al., 1962).
THE MOLECULAR DEFECT IN SIALIC ACID
STORAGE DISEASE
Chromosome 6q
The Finnish population has a characteristic disease heritage
due to its relative geographic isolation. More than 30 rare re-
cessive disorders of extreme homogeneity have been identified
by positional cloning, and, the gene locus is known in about
half of them (Peltonen et al., 1999). In 1992, Haataja and co-
workers conducted a genetic linkage analysis of 24 families,
where at least one member had SD. They studied 64 gene mark-
ers on 19 autosomes by exclusion mapping and concluded that
chromosome 2q was a likely candidate site for the disease gene
(Haataja et al., 1992). However, extended analysis using 85 re-
striction fragment length polymorphisms (RFLP) and 86 mi-
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crosatellitemarkers provided evidence that the SD gene mapped
to the long arm of chromosome 6. The highest LOD score was
obtained for the marker D6S286, where only one recombina-
tion event occurred (Haataja et al., 1994b).
To define the SD locus further, Schleutker and colleagues
constructeda dense map of 13 microsatelliteson a critical chro-
mosomal segment of 10 centiMorgan (cM) length. Linkage dis-
equilibrium mapping enabled them to assign the gene for SD
to an 80-kb region between 6q14 and 6q15 (Schleutker et al.,
1995a). Three markers, D6S280, D6S406, and D6S456, were
found in 75% of parental SD chromosomes (2-5-4 haplotype).
The same authors studied the haplotypesof 26 non-Finnishfam-
ilies with SD or ISSD, and compared them with existing data
from 50 Finnish SD families. They demonstrated that the two
types of sialic acid storage disorders had a common gene lo-
cus, but varied in their haplotypes. The majority of SD patients
belonged to the 1-3 haplotype, whereas the 7-6 haplotype pre-
dominated among infants with ISSD (Schleutker et al., 1995b).
Leppanen et al. (1996) used the fiber-FISH technique to as-
semble a detailed genetic map of the chromosomal region be-
tween the markers D6S280 and D6S1622, which provided the
basis for cloning of the SD gene.
Lysosomal sialic acid transporter
Soon after the first case reports of patients with SASD had
been published, it was suggested that the underlying cause for
this new inborn error of metabolism was a malfunctioning ac-
tive transport of NeuAc across the lysosomal membrane (Ren-
lund et al., 1983b). This hypothesis was confirmed in a num-
ber of experiments that demonstrated the reduced lysosomal
egress of radiolabeled NANA derivatives from SD and ISSD
fibroblasts(Mancini et al., 1986; Renlund et al., 1986b; Mendla
et al., 1988; Tietze et al., 1989). Mancini and co-workers (1986)
developed an elegant technique to study the flux of free sialic
acid in and out of the lysosome. They measured the uptake of
(14C)NeuAc after purificationand resealing of lysosomal mem-
brane vesicles from rat liver. They demonstrated that NeuAc
and glucuronic acid (GlcUA) entered the lysosome through a
pH-dependent carrier-mediated mechanism (Mancini et al.,
1989). Later, the same group extracted the sialic acid carrier
with a detergent from the lysosomal membrane and success-
fully reconstituted it in egg yolk liposomes (Mancini et al.,
1992a). Havelaar et al. (1998) isolated the functionally active
transport protein in several steps with hydroxyapatite, affinity,
and ion-exchangechromatography.Substrate specificity testing
revealed that the carrier recognized mono- and dicarboxylates
in addition to acidic monosaccharides (Havelaar et al., 1998).
A similar transport system was found to be present in lysoso-
mal membrane vesicles from healthy humans and patients with
SD. The uptake rate for glucuronic acid was high in the con-
trol group, intermediate in obligate heterozygotes, and low in
patients with SD, which was evidence for a recessive mode of
inheritance (Mancini et al., 1991).
SLC17A5 gene
Two main cellular transport systems for the exchange of es-
sential metabolic substances and waste products are known to
occur in living organisms. The ATP-binding cassette super-
family (ABC) facilitates the active transport of micro- and
macromolecules by consumption of ATP, whereas the major
facilitator superfamily (MFS) is capable of transporting small
molecules only using an osmotic gradient across cellular com-
partments. ABC and MFS members constitute about 50% of
transporters in microorganisms and mammals. The molecular
structure of MFS permeases characteristicallyconsists of a sin-
gle protein with two 6-unit transmembrane domains (Pao et al.,
1998). Havelaar and co-authors (1999) tested the kinetic prop-
erties of the sialic acid carrier with representativesubstrates for
the 18 MFS subfamilies. The results suggested that it belonged
either to the monocarboxylate porter family (MCP, No. 13) or
to the anion/cation symporter family (ACS, No. 14), which
made them potential candidates for a gene search (Havelaar et
al., 1999). Verheijen and colleagues (1999) screened existing
cDNA libraries for clones that covered the previously deter-
mined critical gene segment on chromosome 6q. They identi-
fied a new gene, SLC17A5, which encodes a 57-kD polypep-
tide with a predicted transport function and is mutated in
patients with sialic acid storage disorders (Verheijen et al.,
1999). One particular mutation, R39C or SallaFin, which
changes the amino acid arginine at position 115 to cysteine, is
present in 95% of Finnish and Swedish patients with Salla dis-
ease. The same mutation was found in a heterozygous form in
five non-Scandinavian patients. These patients were classified
as intermediate types and showed a more severe clinical pic-
ture. In contrast, the children with ISSD had 10 different mu-
tations, including deletions, insertions, missense, and nonsense
mutations (Aula et al., 2000). The carrier frequency of SallaFin
is 1.87% in the Salla area and 0.44% in the rest of Finland, in-
dicating a founder effect. A minisequencingtest for population-
wide genetic screening is available (Syvanen et al., 1992).
Sialin
The gene product expressed by the SLC17A5 gene consists of
495 amino acids and is homologous to the ACS family, which
comprises 40 transport proteins (Verheijen et al., 1999). It was
named “sialin” becauseof its postulatedrole in the sialic acid stor-
age disorders.This should not be confused with the salivarygland
tetrapeptide “sialin” that has a pH-stabilizing effect on human
saliva (Coulteret al., 1990).Alignmentof the amino acid sequence
showed that they lysosomal membrane protein “sialin” is 37%
identical and 61% similar to a human brain-specific Na1-depen-
dent inorganic phosphate cotransporter (hBNPI). This protein is
expressed solely in neurons and glia cells, where it is responsible
for the import of inorganic phosphate (Ni et al., 1996). Sequence
comparison with a sodium-dependentphosphate transport protein
(NPT1), which is predominant in human kidneys, indicated 34%
identity and 57% similarity.
NPT1 is 467 amino acids long and contributes to the phos-
phate equilibrium in the proximal renal tubules (Chong et al.,
1993). Analysis by computer-aided topology and a hydropho-
bicity plot suggested that “sialin” has 12 transmembrane re-
gions (TM-domains) and six N-glycosylation sites. The fourth
TM-domain is characteristic for members of the anion/cation
symporter family. Preliminary comparative modeling studies
using the SAS/FASTA program revealed partial homology of
“sialin” with halorhodopsin and the human glucose transporter
type 1 (GTR1).
Halorhodopsin is a light-driven chloride pump found in
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Halobacteriumsalinarum. It functions as a photosynthetic re-
action center and consists mainly of membrane-spanninga-he-
lix pairs. Halorhodopsin is homologous to “sialin” from amino
acid position 43 to 289 and shows 30% identity.
The human glucose transporter type 1 belongs to the family
of glucose transporters and is expressed as integral membrane
protein in many human tissues. It is responsible for constitu-
tive or basal glucose uptake and has a broad substrate speci-
ficity, which includes various pentoses and hexoses. The glu-
cose transporter is encoded by the SLC2A1 gene or GLUT1
gene. GTR1 contains predominantly a-helices and is homolo-
gous to “sialin” between positions 295 and 504, including gap
segments. It shows 26.3% identity to “sialin” (Strehle, 2002).
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